The Cancer Genome Atlas (TCGA-PanCancer Atlas) ovarian serous carcinoma dataset showed that 67% (368/584 cases) of patients with ovarian cancer (total = 584 cases) retained the TP53 gene mutations, including missense (59.7%: 228 cases), truncating (27.5%: 105 cases), in-frame (3.1%: 12 cases), splice (9.3%: 36 cases), and fusion (0.2%: one case) types (Fig. 7A, B). This evidence concerns the gene TP53 and ovarian serous carcinoma.